OUR VACCINE PIPELINE
From Bench to Clinic
AAHI is uniquely positioned to support development of products based on our immune-enhancing platforms from bench to clinic. Our capabilities place AAHI at the intersection of emerging sciences, medicine, and the business of biotech, enabling us to provide technologies, services, and insights that advance the state-of-the art for the entire biomedical community.
Formulation and
RNA Vaccine Development
R&D manufacturing for preclinical, immunogenicity, and GLP toxicity studies
Product Development and Characterization
cGMP Manufacturing and QA/QC
Consulting Clinical/Regulatory Services
Alleviating Disease Around the World
INDICATION | Preclinical | GMP/Tox | Phase 1 | Phase 2 | Phase 3 |
|---|---|---|---|---|---|
COVID-19 | Protein Vaccine Candidates | ||||
RNA Vaccine | |||||
Tuberculosis | Protein Vaccine Candidates | ||||
HIV | Protein Vaccine Candidates | ||||
Flavivirus | |||||
Pandemic Influenza | Spray-dried | ||||
Bivalent (H7N9, H5N1) | |||||
Malaria | Protein Vaccine Candidates | ||||
Hepatitis C | Protein Vaccine Candidate | ||||
Neglected Tropical Diseases | Hookworm | ||||
Schistosomiasis | |||||
Schistosomiasis | |||||
Leprosy |